Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
The new research might make self-injection of this antiretroviral therapy (ART) a more feasible option. But the study published in Clinical Infectious Diseases by scientists at GSK and ViiV ...